Axa S.A. Has $225.59 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Axa S.A. grew its holdings in Zoetis Inc. (NYSE:ZTS) by 10.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,301,285 shares of the company’s stock after purchasing an additional 126,070 shares during the period. Zoetis comprises 0.7% of Axa S.A.’s portfolio, making the stock its 26th largest holding. Axa S.A. owned about 0.29% of Zoetis worth $225,591,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Asset Dedication LLC raised its stake in Zoetis by 4.8% during the second quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock worth $204,000 after acquiring an additional 54 shares in the last quarter. Angeles Wealth Management LLC grew its stake in Zoetis by 3.5% during the fourth quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after buying an additional 56 shares during the last quarter. Forza Wealth Management LLC raised its stake in shares of Zoetis by 1.8% in the second quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after acquiring an additional 58 shares during the last quarter. L. Roy Papp & Associates LLP grew its position in Zoetis by 2.8% during the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock worth $385,000 after acquiring an additional 60 shares during the last quarter. Finally, Edge Capital Group LLC increased its holdings in Zoetis by 3.7% during the 2nd quarter. Edge Capital Group LLC now owns 1,786 shares of the company’s stock valued at $310,000 after purchasing an additional 64 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent analyst reports. Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $220.38.

Zoetis Trading Up 0.0 %

NYSE:ZTS opened at $193.68 on Wednesday. The firm has a market capitalization of $87.75 billion, a price-to-earnings ratio of 37.32, a PEG ratio of 2.97 and a beta of 0.88. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The business’s 50-day moving average price is $185.22 and its two-hundred day moving average price is $174.50. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the company posted $1.41 EPS. On average, equities analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.